Jaromı́r Roubec

8.6k total citations · 1 hit paper
23 papers, 1.7k citations indexed

About

Jaromı́r Roubec is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Hepatology. According to data from OpenAlex, Jaromı́r Roubec has authored 23 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 3 papers in Hepatology. Recurrent topics in Jaromı́r Roubec's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (10 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Jaromı́r Roubec is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (10 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Jaromı́r Roubec collaborates with scholars based in Czechia, United States and Germany. Jaromı́r Roubec's co-authors include Miloš Pešek, E. Kaukel, Joachim von Pawel, U. Gatzemeier, A Płużańska, János Strausz, Georgy M. Manikhas, Rodryg Ramlau, Piotr Serwatowski and Aleksandra Szczęsna and has published in prestigious journals such as Journal of Clinical Oncology, Molecular Cancer Therapeutics and Journal of Thoracic Oncology.

In The Last Decade

Jaromı́r Roubec

18 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

2007 706 citations U. Gatzemeier, A Płużańska et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jaromı́r Roubec Czechia	9	1.3k	1.3k	574	170	75	23	1.7k
Jacqui Rowbottom United Kingdom	10	1.2k 1.0×	791 0.6×	567 1.0×	321 1.9×	127 1.7×	14	1.6k
Ira A. Oliff United States	8	1.3k 1.0×	1.2k 1.0×	451 0.8×	226 1.3×	61 0.8×	12	1.7k
Thomas Goddemeier Germany	9	966 0.8×	930 0.7×	352 0.6×	179 1.1×	52 0.7×	18	1.3k
Dora Hatzidaki Greece	22	1.1k 0.9×	819 0.6×	390 0.7×	373 2.2×	79 1.1×	67	1.5k
Tsveta Milenkova United Kingdom	15	1.0k 0.8×	906 0.7×	467 0.8×	546 3.2×	150 2.0×	32	1.5k
Erina Hatashita Japan	15	579 0.5×	492 0.4×	588 1.0×	130 0.8×	126 1.7×	17	1.0k
P. Fidias United States	14	882 0.7×	971 0.8×	307 0.5×	116 0.7×	87 1.2×	39	1.3k
V. Damiano Italy	15	796 0.6×	568 0.4×	502 0.9×	181 1.1×	78 1.0×	34	1.3k
Xiaoqing Liu China	19	916 0.7×	1.0k 0.8×	407 0.7×	462 2.7×	123 1.6×	70	1.5k
Yuichi Sakamori Japan	19	1.0k 0.8×	932 0.7×	330 0.6×	146 0.9×	71 0.9×	81	1.5k

Countries citing papers authored by Jaromı́r Roubec

Since Specialization

Citations

This map shows the geographic impact of Jaromı́r Roubec's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaromı́r Roubec with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaromı́r Roubec more than expected).

Fields of papers citing papers by Jaromı́r Roubec

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaromı́r Roubec. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaromı́r Roubec. The network helps show where Jaromı́r Roubec may publish in the future.

Co-authorship network of co-authors of Jaromı́r Roubec

This figure shows the co-authorship network connecting the top 25 collaborators of Jaromı́r Roubec. A scholar is included among the top collaborators of Jaromı́r Roubec based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaromı́r Roubec. Jaromı́r Roubec is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reinmuth, Niels, Mustafa Özgüroğlu, Natasha B. Leighl, et al.. (2023). LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study. Immuno-Oncology Technology. 20. 100692–100692. 2 indexed citations

Tomášková, Hana, et al.. (2023). Changes in the Heart Rate of Sniffer Dogs Trained for Detection of Lung Cancer. Diagnostics. 13(15). 2567–2567. 1 indexed citations

Roubec, Jaromı́r, et al.. (2022). Olfactometric diagnosis of lung cancer by canine scent – A double-blinded study. Complementary Therapies in Medicine. 64. 102800–102800. 3 indexed citations

Navarro, Alejandro, Santiago Ponce Aix, Egbert F. Smit, et al.. (2022). Analysis of patients with relapsed small cell lung cancer (SCLC) receiving single-agent lurbinectedin in the phase 3 ATLANTIS trial.. Journal of Clinical Oncology. 40(16_suppl). 8524–8524. 6 indexed citations

Pešek, Miloš, Vı́tězslav Kolek, Leona Koubková, et al.. (2018). Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic. Klinicka onkologie. 31(3). 207–212.

Skřičková, Jana, Zbyněk Bortlíček, Miloš Pešek, et al.. (2017). P2.03-023 Characteristics of NSCLC Patients Treated in First Line Treatment with Tyrosine Kinase Inhibitors (TKI) - Real Data from the Czech Republic. Journal of Thoracic Oncology. 12(11). S2136–S2136. 1 indexed citations

Skřičková, Jana, Karel Hejduk, Miloš Pešek, et al.. (2014). Gefitinib in front line treatment of patients with NSCLC in the Czech Republic: Analysis of 113 patients. 44. 2721.

Roubec, Jaromı́r, Karel Hejduk, Zbyněk Bortlíček, et al.. (2013). TLUNG registry: data analysis of patients with non-squamousNSCLC (adenocarcinoma, large cell carcinoma) and PS 0-1 treatedwith erlotinib in second line setting.. 1 indexed citations

Kolek, V., Leona Koubková, Jaromı́r Roubec, et al.. (2012). Oral vinorelbine in combination with carboplatin in adjuvant chemotherapy of non-small cell lung cancer (NSCLC): A prospective multicentre study of feasibility, tolerability and short time survival. Lung Cancer. 77. S34–S34.

10.

Skřičková, Jana, Zbyněk Bortlíček, Karel Hejduk, et al.. (2012). Nové možnosti nákladné pneumoonkologické léčby pokročilého nemalobuněčného karcinomu plic (NSCLC) v první linii dle morfologické a molekulárně genetické diagnostiky v České republice. 6(2). 79–82.

11.

Kim, Sang‐We, Hon‐Ki Hsu, Gürsel Çok, et al.. (2009). Patient attitudes towards chemotherapy and survival: A prospective observational study in advanced non-small cell lung cancer. Lung Cancer. 66(2). 250–256. 10 indexed citations

12.

Giaccone, Giuseppe, Petr Zatloukal, Jaromı́r Roubec, et al.. (2009). Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 27(27). 4481–4486. 210 indexed citations

13.

Giaccone, Giuseppe, Petr Zatloukal, Jaromı́r Roubec, et al.. (2007). A phase II, monotherapy study of YM155, a novel survivin suppressant, in previously treated advanced stage non-small cell lung cancer (NSCLC). Molecular Cancer Therapeutics. 6. 2 indexed citations

14.

Gatzemeier, U., A Płużańska, Aleksandra Szczęsna, et al.. (2007). Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial. Journal of Clinical Oncology. 25(12). 1545–1552. 706 indexed citations breakdown →

15.

Heymach, John V., Bruce E. Johnson, Diane Prager, et al.. (2007). Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 25(27). 4270–4277. 232 indexed citations

16.

Heymach, John V., Bruce E. Johnson, Diane Prager, et al.. (2006). A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results. Journal of Clinical Oncology. 24(18_suppl). 7016–7016. 53 indexed citations

17.

Herbst, Regina, Barry C. Johnson, Jacqui Rowbottom, et al.. (2005). O-100 ZD6474 plus docetaxel in patients with previously treatedNSCLC: Results of a randomized, placebo-controlled Phase II trial. Lung Cancer. 49. S35–S36. 22 indexed citations

18.

Gatzemeier, U., A Płużańska, A. Szczęsna, et al.. (2004). Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 22(14_suppl). 7010–7010. 248 indexed citations

19.

Zatloukal, Petr, Luboš Petruželka, Milada Zemanová, et al.. (2003). Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer. 41(3). 321–331. 139 indexed citations

20.

Zatloukal, Petr, Luboš Petruželka, Milada Zemanová, et al.. (2003). O-220 Gemcitabine plus cisplatin versus gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: A phase III randomized trial. Lung Cancer. 41. S65–S65. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact